Jiangsu and Kailera report positive topline data for 8mg HRS9531 GLP-1/GIP owenhaskins Jan 20, 2025 3 min read Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have announced positive topline data from the 8mg dose of Hengrui Pharmas Phase 2 clinical trial (HRS9531-203) of HRS9531, a GLP-1/GIP receptor dual agonist, in individuals living with obesity or overweight
There are not any new safety concerns beyond those of similar medications
Some plans add requirements like nutritional counseling, behavioral therapy documentation, or evidence that other weight loss medications were tried first
You log your progress, track your doses, request refills, and message your care team about side effects or dosing questions
In the pivotal SURPASS clinical trial program evaluating tirzepatide for type 2 diabetes, arthralgia was documented as an adverse event, but occurred at similar rates in both tirzepatide and comparator groups, suggesting it may not be directly attributable to the medication itself
International Recommendations for the Management of Adults Treated With Ketogenic Diet Therapies
.png)
